NOT-DA-03-021: RODENT AND MONKEY TESTING FOR NIDA MEDICATION DISCOVERY PROGRAMS

Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health^®


RODENT AND MONKEY TESTING FOR NIDA MEDICATION DISCOVERY PROGRAMS

Release Date:  August 8, 2002

NOTICE:  NOT-DA-03-021

RFP AVAILABLE:  N01DA-3-8823

National Institute on Drug Abuse (NIDA)

The National Institute of Drug Abuse (NIDA) is soliciting proposals from 
qualified organizations having in-house capability to perform in vivo 
rodent and primate pharmacology studies of potential pharmacotherapies 
for drug dependence disorders.  The primary emphasis is on testing 
conducted for NIDA"s Opiod Treatment Discovery program.  The objectives 
of this requirement are: (1) to determine the in vivo receptor activity 
of novel compounds, (2) to determine the effects of compounds in opiate-
dependent animals, primarily during opiate withdrawal, (3) to evaluate 
compounds for their potential suitability for clinical trials as relapse 
prevention agents, and (4) to identify and acquire standard compounds 
which merit the aforementioned types of evaluation.  In addition, this 
contract shall support follow-up rodent and/or rodent and/or primate 
pharmacology studies of compounds identified as promising potential drug 
dependence treatment agents. 

This requirement is a follow-on procurement to contract number N01DA-8-
8088 with Virginia Commonwealth University.   The contract work will 
require the contractor to perform blind tests on the identity of 
proprietary test compounds, and evaluate the compounds in established 
assays. The NIDA Medications Development Division will utilize the 
resulting data.  In order to handle substances under the Controlled 
Substances Act of 1970, the successful offeror must indicate possession 
of a current DEA registration for Schedule II-V substances prior to 
award, and must demonstrate the ability to obtain DEA registration for 
Schedule I controlled substances.  

NIDA anticipates that a 5-year incrementally funded completion-type 
contract with options for additional supplies and labor hours will 
result from this procurement.  

RFP No. N01DA-3-8823 will be available electronically about August 14, 
2002 and interested sources may access it through the Internet at: 
www.fedbizopps.gov or through the NIDA website address: 
www.nida.nih.gov/RFP/RFPList.html.  NIDA will issue a streamlined RFP 
for this acquisition to include only the Work Statement, Deliverables 
and Reporting Requirements, Special Requirements and Mandatory 
Qualifications, Technical Evaluation Criteria, and other necessary 
Proposal Preparation Instructions.  Proposals will be due about October 
7, 2002. Following proposal submission and the initial review process, 
the Contracting Officer may require additional documentation from 
offerors in the competitive range.  This advertisement does not commit 
the Government to award a contract.  

Point of Contact:

Diane M. Loeb 
Contract Specialist
National Institute on Drug Abuse
Contracts Management Branch, OPRM
6001 Executive Boulevard
Room 3105, MSC 9543
Bethesda, Maryland  20892-9543
Electronic Mail Address: [email protected]
Telephone:  (301) 443-6677
Fax:  (301) 443-7595
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices